Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.
Health resource use
Neuroendocrine tumors
Somatostatin analogs
Treatment patterns
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
09
09
2019
accepted:
05
12
2019
pubmed:
31
1
2020
medline:
22
6
2021
entrez:
31
1
2020
Statut:
ppublish
Résumé
Although an increasing number of treatments have become available for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), there remains little consensus on treatment sequence and its impact on health care resource use (HRU). We sought to describe treatment patterns and HRU, in a cohort of patients with metastatic GEP-NETs treated at a tertiary referral center in the U.S. We identified patients with a well-differentiated, metastatic GEP-NET evaluated at Dana-Farber Cancer Institute between July 2003 and May 2015. For these patients, we describe the sequence of treatment regimens received for their disease, together with associated HRU. We identified 682 patients with advanced GEP-NETs. Of these patients, 597 (87.0%) initiated ≥1 treatment over the follow-up period. The mean age at diagnosis was 58.5 years, 50.2% were men, and 94.0% were white. A total of 83.1% initiated a somatostatin analog (SSA) as their first-line treatment, with 55% and 31% of patients continuing with second- and third-line therapies. A total of 31.2% of patients with SSAs underwent dose escalation to above standard dose. In this setting, patients with pancreatic neuroendocrine tumors were more commonly treated with cytotoxic regimens than other NET tumor types and also had higher HRU. Our study suggests that, at a tertiary referral center, patients with advanced NETs commonly received multiple courses of treatments. Our data suggest a clear preference for use of SSAs as a first-line treatment for patients with advanced NETs, with SSAs commonly escalated and continued throughout the course of treatment in combination with other regimens. The current study demonstrates the common use of somatostatin analog as a first-line therapy for patients with advanced gastroenteropancreatic neuroendocrine tumors as well as the incorporation of multiple different treatment regimens in the treatment course of patients with this disease.
Sections du résumé
BACKGROUND
Although an increasing number of treatments have become available for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), there remains little consensus on treatment sequence and its impact on health care resource use (HRU). We sought to describe treatment patterns and HRU, in a cohort of patients with metastatic GEP-NETs treated at a tertiary referral center in the U.S.
MATERIALS AND METHODS
We identified patients with a well-differentiated, metastatic GEP-NET evaluated at Dana-Farber Cancer Institute between July 2003 and May 2015. For these patients, we describe the sequence of treatment regimens received for their disease, together with associated HRU.
RESULTS
We identified 682 patients with advanced GEP-NETs. Of these patients, 597 (87.0%) initiated ≥1 treatment over the follow-up period. The mean age at diagnosis was 58.5 years, 50.2% were men, and 94.0% were white. A total of 83.1% initiated a somatostatin analog (SSA) as their first-line treatment, with 55% and 31% of patients continuing with second- and third-line therapies. A total of 31.2% of patients with SSAs underwent dose escalation to above standard dose. In this setting, patients with pancreatic neuroendocrine tumors were more commonly treated with cytotoxic regimens than other NET tumor types and also had higher HRU.
CONCLUSION
Our study suggests that, at a tertiary referral center, patients with advanced NETs commonly received multiple courses of treatments. Our data suggest a clear preference for use of SSAs as a first-line treatment for patients with advanced NETs, with SSAs commonly escalated and continued throughout the course of treatment in combination with other regimens.
IMPLICATIONS FOR PRACTICE
The current study demonstrates the common use of somatostatin analog as a first-line therapy for patients with advanced gastroenteropancreatic neuroendocrine tumors as well as the incorporation of multiple different treatment regimens in the treatment course of patients with this disease.
Identifiants
pubmed: 31999024
doi: 10.1634/theoncologist.2019-0691
pmc: PMC7160404
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e644-e650Informations de copyright
© 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Références
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
Oncologist. 2016 Jun;21(6):671-5
pubmed: 27226359
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Pancreas. 2018 Feb;47(2):173-182
pubmed: 29206668
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Digestion. 2017;96(2):67-75
pubmed: 28728148
J Gastrointest Oncol. 2019 Aug;10(4):674-687
pubmed: 31392048
Gastrointest Cancer Res. 2013 May;6(3):81-5
pubmed: 23936548
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Oncologist. 2014 Sep;19(9):930-6
pubmed: 25096997
Pancreas. 2017 Jul;46(6):707-714
pubmed: 28609356
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Br J Cancer. 2010 Mar 30;102(7):1106-12
pubmed: 20234360
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Cancer. 2011 Jan 15;117(2):268-75
pubmed: 20824724
J Clin Oncol. 2008 Sep 10;26(26):4311-8
pubmed: 18779618
World J Gastroenterol. 2017 Sep 7;23(33):6128-6136
pubmed: 28970728
Endocr Relat Cancer. 2014 May 06;21(3):R153-63
pubmed: 24322304